First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer. Biomol Biomed [Internet]. 2022 Sep. 16 [cited 2024 Apr. 29];22(5):818-25. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7069